Franz Schnetzinger is Head of Process and Analytical Development at AAVantgarde Bio, where he works on implementing the viral vector manufacturing and testing strategy for the company’s AAV programs. Franz has more than 15 years of experience in development, validation, and tech transfer of analytical methods for QC release and stability testing of biologics, vaccines, and advanced therapies across all stages of product development. His focus is on creating a holistic product control and characterization strategy through identification of innovative technologies for high quality product manufacturing and testing. Previously, Franz worked in Quality Control, analytical method development, and innovative technology development for cell and gene therapy and vaccine products at Baxter AG, GSK, Gyroscope Therapeutics and CEPI. Franz obtained a BSc in Bioengineering & Bioinformatics from the University of Applied Sciences Vienna, Austria, in 2011 and graduated from Cranfield University, UK, with a MSc in Analytical Biotechnology in 2012. Since 2020, he has supported the creation of guidelines for product development and characterization as a member of the working group on Advanced Therapies Medicinal Products in the British Pharmacopoeia.
Franz Schnetzinger is Head of Process and Analytical Development at AAVantgarde Bio, where he works on implementing the viral vector manufacturing and testing strategy for the company’s AAV programs. Franz has more than 15 years of experience in development, validation, and tech transfer of analytical methods for QC release and stability testing of biologics, vaccines, and advanced therapies across all stages of product development. His focus is on creating a holistic product control and characterization strategy through identification of innovative technologies for high quality product manufacturing and testing. Previously, Franz worked in Quality Control, analytical method development, and innovative technology development for cell and gene therapy and vaccine products at Baxter AG, GSK, Gyroscope Therapeutics and CEPI. Franz obtained a BSc in Bioengineering & Bioinformatics from the University of Applied Sciences Vienna, Austria, in 2011 and graduated from Cranfield University, UK, with a MSc in Analytical Biotechnology in 2012. Since 2020, he has supported the creation of guidelines for product development and characterization as a member of the working group on Advanced Therapies Medicinal Products in the British Pharmacopoeia.